Emodin as a Multi-Target Modulator of Tumor Angiogenesis: Mechanisms, Microenvironment, and Therapeutic Potential

Angiogenesis is central to tumor development and metastasis because it facilitates oxygen and nutrient supplies to cancer cells. Inhibiting angiogenic pathways is a commonly used strategy in the treatment of cancer, usually through inhibitory actions that first determine targeted apoptosis of the key proangiogenic factor, vascular endothelial growth factor (VEGF), and its upstream regulator, hypoxia-inducible factor 1-alpha (HIF-1α). Emodin, a common anthraquinone derivative of natural origins, has a variety of actions to inhibit angiogenesis, which include the ability to inhibit the expression of VEGF, as well as the ability to reverse stabilization of HIF-1α and inhibit tumor microvessel branching. Moreover, emodin is recognized for pathways other than those involving VEGF, such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF), which impact endothelial cell proliferation and pericyte recruitment. Emodin can facilitate vessel destabilization by acting on several angiopoietins, causing the function of the tumor vasculature to be disrupted. Molecular docking studies have shown emodin can bind the ATP-binding pocket of VEGFR-2 and the degradation domain of HIF-1α, acting as a multi-target inhibitory compound. These mechanisms collectively obstruct tumor vascularization, deprive tumor cells of vital nutrients, and prevent cancer progression. Pre-clinical studies to date have determined it to be a significant anti-angiogenic agent and a synergistic agent in combination with chemotherapy and/or targeted therapies that can be given to patients. Future studies will address bioavailability issues, target the associated resistance mechanisms, and explore ways to increase its efficacy as an adjuvant in cancer treatment.